Skip to main content
. 2018 Aug 14;14(8):e8202. doi: 10.15252/msb.20188202

Figure 4. Combined pharmacologic inhibition of TOP2A and CCNB1 synergistically inhibits CRPC cell proliferation.

Figure 4

  1. The CRPC cell line 22Rv1 was cultured in 2% CSS media and treated for 72 h with vehicle (DMSO), doxorubicin (DOX), N9‐isopropylolomoucine (N‐9), or the combination of DOX and N‐9 at different concentrations. Cell confluence was monitored using Incucyte Zoom System, and the experiments were done with eight replicates each. The data were analyzed using Compusyn software, and a normalized isobologram was built. The table shows the combination index (CI) for the different drug combinations. CI = 1 represents additivity, CI < 1 synergism, and CI > 1 antagonistic effects.
  2. The non‐tumorigenic prostate epithelial cell line RWPE‐1, the AR‐null PC cell line PC‐3, the androgen‐dependent cell line LNCaP, and the CRPC cell lines C4‐2B and 22Rv1 were treated for 72 h with vehicle (DMSO), DOX [100 ng/ml (184 nM)], N‐9 [200 ng/ml (613 nM)], or the combination of DOX [100 ng/ml (184 nM)] and N‐9 [200 ng/ml (613 nM)]. C4‐2B and 22Rv1 cells were kept in 10% CSS media, and the other cell lines were kept in 10% FBS. Cell confluence was monitored using the Incucyte Zoom System. Data represent two independent experiments, with four to six replicates each, showing the mean ± s.e.m., and normalized to vehicle controls. Kruskal–Wallis test, (P‐value < 0.0001, two‐tailed) and Dunn's multiple comparisons test were performed. *P‐value < 0.05, **P‐value < 0.01, ***P‐value < 0.001.
  3. The non‐tumorigenic prostate cell line RWPE‐1 and the CRPC cell line 22Rv1 were treated for 72 h with vehicle (DMSO) or the combination of DOX and N‐9 at 100 ng/ml and N‐9 200 ng/ml, respectively. Cell confluence was monitored using the Incucyte Zoom System and representative images are shown.

Source data are available online for this figure.